REGENXBIO Faces Securities Litigation Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy RGNX?
Source: Globenewswire
- Litigation Investigation: Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO for investors who purchased securities between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 due to a neoplasm case in a trial participant, leading to decreased investor confidence in product safety.
- Significant Stock Drop: Following the FDA announcement, REGENXBIO's stock price fell by $2.40, or 17.9%, closing at $11.01 per share, reflecting market concerns regarding the company's future prospects.
- Investor Rights Reminder: Faruqi & Faruqi reminds investors that April 14, 2026, is the deadline to apply as lead plaintiff in the federal securities class action, emphasizing that participation in the legal process may affect their recovery outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.040
Low
19.00
Averages
29.71
High
45.00
Current: 8.040
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REGENXBIO Faces Class Action Lawsuit
- Lawsuit Background: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, alleging the company misled investors regarding the viability of its drug candidate RGX-111.
- Drug Safety Issues: The complaint claims that while REGENXBIO touted RGX-111's FDA Fast Track designation in 2018 and reported positive clinical trial results, the company was aware of serious safety concerns, including the potential for central nervous system tumors.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 after a participant developed an intraventricular CNS tumor, causing REGENXBIO's stock to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
- Shareholder Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 14, 2026, while those who choose not to participate can remain absent class members eligible for recovery.
See More
REGENXBIO Faces Class Action Lawsuit Over Allegations of Misleading Information
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against REGENXBIO in the U.S. District Court for the Southern District of Maryland on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that REGENXBIO misled investors regarding the development of its gene therapy RGX-111 by providing overly optimistic trial success forecasts while concealing critical adverse facts about the trial's safety and efficacy, potentially leading to investor losses.
- Stock Price Plunge: Following the FDA's clinical hold on RGX-111, REGENXBIO's stock price plummeted from $13.41 per share on January 27, 2026, to $11.01 on January 28, representing a 17.8% decline in just one day, reflecting strong market concerns about the company's future.
- Investor Rights Protection: Affected investors have until April 14, 2026, to apply to be lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to help investors understand their legal rights and potential remedies.
See More
REGENXBIO Faces Securities Litigation Investigation
- Litigation Investigation: Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO for investors who purchased securities between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 due to a neoplasm case in a trial participant, leading to decreased investor confidence in product safety.
- Significant Stock Drop: Following the FDA announcement, REGENXBIO's stock price fell by $2.40, or 17.9%, closing at $11.01 per share, reflecting market concerns regarding the company's future prospects.
- Investor Rights Reminder: Faruqi & Faruqi reminds investors that April 14, 2026, is the deadline to apply as lead plaintiff in the federal securities class action, emphasizing that participation in the legal process may affect their recovery outcomes.
See More
Class Action Lawsuit Announced for REGENXBIO Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of REGENXBIO (NASDAQ: RGNX) securities purchasers from February 9, 2022, to January 27, 2026, indicating potential investor losses due to misleading information.
- Compensation Structure: Investors joining the lawsuit may receive compensation without any upfront costs, demonstrating the law firm's commitment to protecting investor rights while potentially attracting more affected investors to participate.
- Case Background: The lawsuit alleges that REGENXBIO provided false and misleading information regarding its RGX-111 gene therapy product development, resulting in investor losses when the true details emerged, highlighting significant deficiencies in the company's information disclosure practices.
- Law Firm's Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against REGENXBIO, seeking damages for investors who purchased securities between February 9, 2022, and January 27, 2026, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that REGENXBIO made materially false and misleading statements regarding its plan to develop and commercialize RGX-111, particularly concerning the anticipated success of its clinical trials, which may have misled investors about the company's prospects.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by April 14, 2026, to share in any potential recovery, highlighting the legal system's commitment to protecting investor rights in securities fraud cases.
- Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is a well-respected firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its vital role in upholding market integrity.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiation: The Portnoy Law Firm has notified REGENXBIO investors of a class action lawsuit for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a nearly 18% drop in stock price, raising concerns about the product's safety and efficacy.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, demonstrating a commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology firm focused on gene therapies, developing RGX-111 for treating severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by ongoing legal challenges.
See More
REGENXBIO Faces Class Action Lawsuit
- Lawsuit Background: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, alleging the company misled investors regarding the viability of its drug candidate RGX-111.
- Drug Safety Issues: The complaint claims that while REGENXBIO touted RGX-111's FDA Fast Track designation in 2018 and reported positive clinical trial results, the company was aware of serious safety concerns, including the potential for central nervous system tumors.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 after a participant developed an intraventricular CNS tumor, causing REGENXBIO's stock to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
- Shareholder Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 14, 2026, while those who choose not to participate can remain absent class members eligible for recovery.
See More
REGENXBIO Faces Class Action Lawsuit Over Allegations of Misleading Information
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against REGENXBIO in the U.S. District Court for the Southern District of Maryland on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that REGENXBIO misled investors regarding the development of its gene therapy RGX-111 by providing overly optimistic trial success forecasts while concealing critical adverse facts about the trial's safety and efficacy, potentially leading to investor losses.
- Stock Price Plunge: Following the FDA's clinical hold on RGX-111, REGENXBIO's stock price plummeted from $13.41 per share on January 27, 2026, to $11.01 on January 28, representing a 17.8% decline in just one day, reflecting strong market concerns about the company's future.
- Investor Rights Protection: Affected investors have until April 14, 2026, to apply to be lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to help investors understand their legal rights and potential remedies.
See More
REGENXBIO Faces Securities Litigation Investigation
- Litigation Investigation: Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO for investors who purchased securities between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 due to a neoplasm case in a trial participant, leading to decreased investor confidence in product safety.
- Significant Stock Drop: Following the FDA announcement, REGENXBIO's stock price fell by $2.40, or 17.9%, closing at $11.01 per share, reflecting market concerns regarding the company's future prospects.
- Investor Rights Reminder: Faruqi & Faruqi reminds investors that April 14, 2026, is the deadline to apply as lead plaintiff in the federal securities class action, emphasizing that participation in the legal process may affect their recovery outcomes.
See More
Class Action Lawsuit Announced for REGENXBIO Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of REGENXBIO (NASDAQ: RGNX) securities purchasers from February 9, 2022, to January 27, 2026, indicating potential investor losses due to misleading information.
- Compensation Structure: Investors joining the lawsuit may receive compensation without any upfront costs, demonstrating the law firm's commitment to protecting investor rights while potentially attracting more affected investors to participate.
- Case Background: The lawsuit alleges that REGENXBIO provided false and misleading information regarding its RGX-111 gene therapy product development, resulting in investor losses when the true details emerged, highlighting significant deficiencies in the company's information disclosure practices.
- Law Firm's Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against REGENXBIO, seeking damages for investors who purchased securities between February 9, 2022, and January 27, 2026, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that REGENXBIO made materially false and misleading statements regarding its plan to develop and commercialize RGX-111, particularly concerning the anticipated success of its clinical trials, which may have misled investors about the company's prospects.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by April 14, 2026, to share in any potential recovery, highlighting the legal system's commitment to protecting investor rights in securities fraud cases.
- Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is a well-respected firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its vital role in upholding market integrity.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiation: The Portnoy Law Firm has notified REGENXBIO investors of a class action lawsuit for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a nearly 18% drop in stock price, raising concerns about the product's safety and efficacy.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, demonstrating a commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology firm focused on gene therapies, developing RGX-111 for treating severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by ongoing legal challenges.
See More
